Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReCIPE-M1: Radiation, Plasma Exchange, and Immunotherapy in Melanoma
NCT04581382Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Dec 2020
- Primary completion
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab and nivolumab in melanoma, sponsored by Mayo Clinic. Primary endpoints: Feasibility of treatment approach up to 2 years and Kinetics of soluble (s)PD-L1 removal and regeneration up to 2 years. Started Dec 2020; status: completed.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04581382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04581382.